beta
Trial Radar AI
Clinical Trial NCT07490691 (PH-GRIEF) for Loss-Related Depression, Interpersonal Loss, Complicated Grief is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

Painhunting Therapy for Interpersonal Loss-Related Depression (PH-GRIEF) 72 Randomized Remote

Not yet recruiting
Clinical Trial NCT07490691 (PH-GRIEF) is an interventional study for Loss-Related Depression, Interpersonal Loss, Complicated Grief and is currently not yet recruiting. Enrollment is planned to begin on 23 March 2026 and continue until the study accrues 72 participants. Led by Painhunting LLP, this study is expected to complete by 30 October 2026. The latest data from ClinicalTrials.gov was last updated on 24 March 2026.
Brief Summary
This pilot randomized controlled trial evaluates the efficacy of Painhunting therapy, a brief structured psychotherapy, for adults with significant interpersonal loss and comorbid depressive symptoms in Kazakhstan. Seventy-two participants will be randomly assigned to receive either immediate Painhunting therapy (3 sessions over 3-4 weeks) or a 4-week waitlist control condition. Therapy is delivered in-person in Asta...Show More
Detailed Description
Interpersonal loss, including experiences such as relationship dissolution, betrayal, abandonment, or the death of a close person, is a significant psychological stressor that can lead to persistent emotional distress, depressive symptoms, and functional impairment. A subset of individuals exposed to interpersonal loss develops prolonged or complicated grief reactions accompanied by depressive symptoms and difficulti...Show More
Official Title

Efficacy of Painhunting Therapy for Interpersonal Loss-Related Depression: A Waitlist-Controlled Randomized Pilot Trial

Conditions
Loss-Related DepressionInterpersonal LossComplicated Grief
Other Study IDs
  • PH-GRIEF
  • PH-GRIEF-RCT1-2026-WL
NCT ID Number
NCT07490691
Start Date (Actual)
2026-03-23
Last Update Posted
2026-03-24
Completion Date (Estimated)
2026-10-30
Enrollment (Estimated)
72
Study Type
Interventional
PHASE
N/A
Status
Not yet recruiting
Keywords
Painhunting Therapy
Interpersonal Loss
Depression
Complicated Grief
Psychotherapy
Emotional Trauma
Randomized Controlled Trial
Primary Purpose
Treatment
Design Allocation
Randomized
Interventional Model
Parallel
Masking
None (Open Label)
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalExperimental - Painhunting Therapy
Three individual psychotherapy sessions (1.5-2 hours each) delivered over 3-4 weeks using the Painhunting therapeutic framework. Sessions are conducted by trained Painhunting practitioners under supervision of a certified Painhunting instructor. Sessions are delivered either in person or via secure video conferencing.
Painhunting Therapy
Painhunting therapy is a structured psychotherapeutic intervention designed to identify emotionally significant past experiences associated with current psychological distress and facilitate emotional processing of these experiences. The intervention consists of three individual sessions delivered over 3-4 weeks by trained practitioners.
No InterventionNo Intervention - Waitlist Control
Participants assigned to the waitlist control group will undergo a 3-4 week waiting period without receiving the intervention. During this period, brief safety monitoring and psychoeducational materials are provided. After completion of the waiting period, participants are offered the Painhunting therapy intervention.
N/A
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Change in PHQ-9 (Patient Health Questionnaire-9) Score
Self-report measure of depression severity (range 0-27). Higher scores indicate more severe depression.
Baseline (T0) to post-treatment/end of wait (T2, approximately week 4)
Change in ICG (Inventory of Complicated Grief) Score
Self-report measure of complicated grief symptoms (range 0-76). Scores of 25 or higher indicate clinically significant complicated grief.
Baseline (T0) to post-treatment/end of wait (T2, approximately week 4)
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Change in GAD-7 Score (Anxiety)
Change in Generalized Anxiety Disorder-7 (GAD-7) Score Self-report measure of anxiety severity (range 0-21). Higher scores indicate more severe anxiety
Time Frame: Baseline (T0) to post-treatment/end of wait (T2, approximately week 4)
Change in PCL-5 Score (PTSD Symptoms)
Change in PTSD Checklist for DSM-5 (PCL-5) Score Self-report measure of PTSD symptoms (range 0-80). Higher scores indicate more severe PTSD symptoms.
Baseline (T0) to post-treatment/end of wait (T2, approximately week 4)
Change in WHO-DAS 2.0 12-Item Score (Functional Disability)
Change in World Health Organization Disability Assessment Schedule 2.0 (WHO-DAS 2.0) 12-item Score Measure of functional disability (range 12-60). Higher scores indicate greater disability.
Baseline (T0) to post-treatment/end of wait (T2, approximately week 4)
Maintenance of Treatment Gains in PHQ-9 and ICG Scores
Maintenance of treatment gains as measured by change in Patient Health Questionnaire-9 (PHQ-9) and Inventory of Complicated Grief (ICG) scores from post-treatment (T2) to 3-month follow-up (T3). PHQ-9 is a self-report measure of depression severity (range 0-27), with higher scores indicating more severe depression. ICG is a self-report measure of complicated grief symptoms (range 0-76), with higher scores indicating more severe grief.
Post-treatment (T2) to 3-month follow-up (T3, approximately week 16)
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All

Age 18 to 65 years

  • PHQ-9 score of 8 or higher
  • ICG score of 25 or higher
  • Interpersonal loss occurring between 6 and 120 months prior to enrollment
  • Willing to accept randomization
  • Proficient in Russian or Kazakh
  • Able to provide informed consent

  • Active suicidal ideation with intent or plan (PHQ-9 item 9 score of 2 or higher, confirmed by clinical interview), with referral to appropriate crisis services if excluded

    • Current psychotic symptoms
    • Active substance use disorder (moderate-severe)
    • Currently receiving psychotherapy
    • Bereavement by suicide
    • Cognitive impairment precluding consent
    • Psychiatric medication initiated within prior 8 weeks
Painhunting LLP logoPainhunting LLP
Study Responsible Party
Uzakova Sanemkhan, Principal Investigator, MD, General Practitioner (licensed physician), Painhunting LLP
Study Central Contact
Contact: Olzhas Seitov, +77017636166, [email protected]
1 Study Locations in 1 Countries

Astana

Painhunting Research Center, Astana, Astana, 010000, Kazakhstan
Olzhas Seitov, Contact, +77017636166, [email protected]
Sanemkhan Uzakova, MD, Contact, +77015193305, [email protected]
Sanemkhan Uzakova, MD, Principal Investigator